My Thoughts

Here are three common fears regarding early-stage strategic partnerships, and ways a founder or investor can overcome them to be successful.

Welcome back to biotech beach! Capital raised in Q1 2024 for San Diego-based life science companies jumped 324% from same period last...

Artificial Intelligence/Machine Learning (AI/ML) has the potential to significantly lower the costs of drug development and improve...

Unfortunately for biotechnology companies, their products have long development timelines and are perceived to be a high-risk investment....

Biotech stocks have been beat up since February 2021, with the XBI index still down ~50% from record highs Headwinds in 2022 stemming from higher interest rates, "risk off" investor sentiment, and regulatory changes and challenges have stymied broad recovery in the sector A mixture of maturing pipelines, significant cash on hand for large pharma, and need for smaller biotechs to collaborate will drive dealmaking in 2023 Biotech investing sentiment will rise and XBI will close

Negative sentiment in the biotech industry has driven the SPDR S&P Biotech ETF (XBI) down more than 30% from February highs....